Literature DB >> 26642721

Tetrandrine Inhibits the Intracellular Calcium Ion Level and Upregulates the Expression of Brg1 and AHNAK in Hep-2 Cells.

Xiangyan Cui, Wei Zhu, Ping Wang, Xin Wang.   

Abstract

BACKGROUND: Tetrandrine has been found to inhibit the growth of various types of tumor cells, but the underlying molecular mechanism remains to be determined. We aimed to investigate the effects of tetrandrine on human laryngeal carcinoma Hep-2 cells.
METHODS: Cell viability was tested using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cell cycle was analyzed using flow cytometric analysis. The intracellular Ca2+ concentration was monitored using the membrane-permeable Ca(2+)-sensitive fluorescent probe fluo-3 acetoxymethyl ester-AM (Fluo3-AM). The mRNA and protein expression of Brgl and AHNAK were evaluated by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunocytochemistry, respectively.
RESULTS: Tetrandrine significantly inhibited the proliferation of Hep-2 cells as indicated by an IC50 value of 13.28 μg/mL. Tetrandrine induced cell cycle arrest at the G1 phase and decreased the intracellular concentration of Ca2+ in a concentration dependent manner. Intriguingly, tetrandrine upregulated Brg1 expression in a dose-and time-dependent pattern and elevated the expression of AHNAK in Hep-2 cells.
CONCLUSIONS: Our results suggest that tetrandrine may inhibit the growth of Hep-2 cells by decreasing the intracellular concentration of Ca2+ and upregulating the expressions of Brg1 and AHNAK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26642721     DOI: 10.7754/clin.lab.2015.141242

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.

Authors:  Yi Xiao Li; Jia Le Wang; Meng Gao; Hao Tang; Rong Gui; Yun Feng Fu
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

2.  Synergistic anti-glioma effect of a coloaded nano-drug delivery system.

Authors:  Huae Xu; Feng Jia; Pankaj Kumar Singh; Shu Ruan; Hao Zhang; Xiaolin Li
Journal:  Int J Nanomedicine       Date:  2016-12-16

3.  AHNAK2 is a potential prognostic biomarker in patients with PDAC.

Authors:  Di Lu; Junxiong Wang; Xiaoyan Shi; Bing Yue; Jianyu Hao
Journal:  Oncotarget       Date:  2017-05-09

Review 4.  Progress on structural modification of Tetrandrine with wide range of pharmacological activities.

Authors:  Liuying Mo; Fan Zhang; Feng Chen; Lei Xia; Yi Huang; Yuemi Mo; Lingqiu Zhang; Daquan Huang; Shunli He; Jiagang Deng; Erwei Hao; Zhengcai Du
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 5.  The Role of BRG1 in Antioxidant and Redox Signaling.

Authors:  Shilong You; Ying Zhang; Jiaqi Xu; Hao Qian; Shaojun Wu; Boquan Wu; Saien Lu; Yingxian Sun; Naijin Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-09-14       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.